Composite Interceptive Med-Sciences Laboratories Private limited (CIMED) is the first pharma company developing the science of “interceptive medicine”, engineering therapeutics to stop, delay and reverse the inexorable progression of chronic diseases linked to lifestyle and aging. CIMED science focus is on safety over long-term use leveraging physiological mechanisms that normally promote healing by the body. We utilize a composite pharmacology- Polymolecular and soft targeting approach using the naturally derived molecular menu as an alternative to early medicalization by synthetic drugs. Our R&D focus also involves orphan areas of medicine where currently there is no standard of care treatments.